T-cell prolymphocytic leukemia (Cancer)
Information
- Disease name
- T-cell prolymphocytic leukemia
- Disease ID
- DOID:0081042
- Description
- "A prolymphocytic leukemia that is characterized by the proliferation of small to medium sized prolymphocytes with a mature T-cell phenotype, involving the blood, bone marrow, lymph nodes, liver, spleen, and skin." [url:https\://pubmed.ncbi.nlm.nih.gov/31082044/]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05010005 | Active, not recruiting | Phase 1 | A Study of Ruxolitinib and Duvelisib in People With Lymphoma | August 12, 2021 | August 2025 |
| NCT03989466 | Active, not recruiting | Phase 1 | Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia | January 15, 2020 | December 31, 2026 |
| NCT04312841 | Active, not recruiting | Phase 2 | Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab | September 15, 2020 | December 31, 2024 |
| NCT01251575 | Completed | Phase 2 | Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | December 1, 2010 | February 11, 2019 |
| NCT02689453 | Completed | Phase 1 | Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) | January 19, 2017 | June 15, 2021 |
| NCT00005803 | Completed | Phase 1/Phase 2 | Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma | September 1999 | October 2018 |
| NCT00060424 | Completed | Phase 2 | Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia | March 2003 | September 22, 2010 |
| NCT01008462 | Completed | Phase 2 | Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia | March 18, 2010 | June 30, 2018 |
| NCT05978141 | Recruiting | A Registry for People With T-cell Lymphoma | July 27, 2023 | July 27, 2030 | |
| NCT05823571 | Recruiting | Phase 1 | Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients | July 6, 2023 | March 2030 |
| NCT02742727 | Unknown status | Phase 1/Phase 2 | CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma | March 2016 | March 2018 |
- Disase is a (Disease Ontology)
- DOID:1039
- Cross Reference ID (Disease Ontology)
- ICDO:9834/3
- Cross Reference ID (Disease Ontology)
- NCI:C4752
- Cross Reference ID (Disease Ontology)
- ORDO:86871
- Exact Synonym (Disease Ontology)
- Prolymphocytic leukemia, T-cell type
- Exact Synonym (Disease Ontology)
- T Cell Prolymphocytic Leukemia